Skip to main content

Advertisement

Advertisement

Asia

South Korea's Celltrion gets approval for Phase 3 trials of COVID-19 antibody drug

South Korea's Celltrion gets approval for Phase 3 trials of COVID-19 antibody drug

FILE PHOTO: Visitors wearing masks to avoid the spread of the coronavirus disease (COVID-19) fill out a form which is mandatory to get into a hospital in Seoul, South Korea, August 26, 2020. REUTERS/Kim Hong-Ji/File Photo

SEOUL: South Korean drugmaker Celltrion said on Monday (Oct 12) it has received regulatory approval for Phase 3 clinical trials of an experimental COVID-19 treatment.

The approval comes as the company plans to seek conditional approval for its antibody drug, CT-P59, for emergency use by the end of this year.

The treatment, the most advanced antibody drug in terms of research in South Korea, is directed against the surface of the virus and designed to block it from locking on to human cells.

READ: South Korea's Celltrion to begin commercial production of COVID-19 antibody drug

The third stage trials will be conducted on about 1,000 asymptomatic coronavirus patients and those who have come into close contact with COVID-19 patients in Korea, Celltrion said in a statement.

The Ministry of Food and Drug Safety recently approved a Phase 2/3 study on patients with mild and moderate cases of COVID-19, Lee Sang-joon, Celltrion's senior executive vice president, told Reuters.

READ: Hong Kong scientists say drug used to treat stomach ulcers successful against coronavirus

Celltrion began commercial production of the drug in September - likely to amount to around 1 million doses - in anticipation of demand in both domestic and overseas markets.

In July, Celltrion separately launched overseas human trials of its treatment in Britain.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram

Source: Reuters/ga

Advertisement

Also worth reading

Advertisement